Revvity, Inc. (RVTY)
(Delayed Data from NYSE)
$121.04 USD
+2.45 (2.07%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $121.00 -0.04 (-0.03%) 7:58 PM ET
4-Sell of 5 4
D Value F Growth B Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$121.04 USD
+2.45 (2.07%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $121.00 -0.04 (-0.03%) 7:58 PM ET
4-Sell of 5 4
D Value F Growth B Momentum F VGM
Zacks News
Revvity (RVTY) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Revvity (RVTY) delivered earnings and revenue surprises of 2.54% and 0.56%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Revvity (RVTY) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Revvity's (RVTY) second-quarter results are likely to reflect weak performance at the Diagnostics segment, partially offset by strong demand for Life Sciences and Diagnostics franchise.
Earnings Preview: Revvity (RVTY) Q2 Earnings Expected to Decline
by Zacks Equity Research
Revvity (RVTY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Revvity (RVTY) Launches Single Solution for Drug Development
by Zacks Equity Research
Revvity (RVTY) Signals Software suite integrates streamlining data, global monitoring and customizable workflows and covers the entire Make-Test-Decide lifecycle, which can be centrally managed.
Revvity (RVTY) Launches New System for Autoimmune Diagnostics
by Zacks Equity Research
Revvity's (RVTY) EUROIMMUN launches UNIQO 160, a new automated system for autoimmune disease diagnostics using indirect immunofluorescence test.